Spinal cord injury drug moves into next phase of trialsRSS Feed

After successfully improving muscle tone in spinal cord injury patients in clinical trials, a new drug is progressing into the next phase of tests.

Arbaclofen placarbil (AP), also known as XP19986, will be tested on multiple sclerosis (MS) patients in Phase 3 clinical trials, the drug's maker biopharmaceutical firm Xenoport has said.

A successful trial with MS sufferers could see the firm filing for a new drug application from the US Food and Drug Administration for the treatment of spasticity.

XenoPort chief executive officer Ronald W Barrett said: "In our previous Phase 2 clinical trial in spinal cord injury patients with spasticity, AP was well tolerated and demonstrated dose-dependent improvement in muscle tone that was maintained throughout the 12-hour dosing interval."

He went on to say that similar results are hoped for in the next phase of clinical trials.

Spasticity is a side effect of paralysis that usually results from damage to the portion of the brain or spinal cord that controls voluntary movement.

Serious Law, award winning spinal injury law firm

Posted by Matthew Dixon
 

Husband 'heartbroken' after wife's spinal cord injury

15 September 2010

A "fantastic mum" who suffered a freak spinal cord injury in a pole-dancing accident could have died had not been for the presence of a nurse friend, the woman's husband has said. As it is,...

Read More...

School rugby rule changes put a stop to spinal injury trend

14 September 2010

A rise in the spinal injury incidence rate in school rugby in Scotland appears to have been stopped after new rules were brought in. The Scottish Rugby Union (SRU) was concerned that the number of schoolboys...

Read More...

Enzyme linked to stem cell behaviour

10 September 2010

Spinal injury patients may see an advance in stem cell research after scientists discovered why certain stem cells do not become another type of cell. A team from John Hopkins University in the US isolated...

Read More...